Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-derived claims largely focus on cough-related content and patient counseling, but many statements are not explicitly supported by the FDA-labeled adverse reactions or counseling sections. The most defensible points are the mechanism (Entresto is not an ACE inhibitor) and general patient-counseling elements (not stopping the drug without medical advice, describing onset and symptoms, and reporting adverse events). Several content items about urgent-care triggers, differential diagnoses, and direct comparative statements versus ACE inhibitors are not present in the labeled information.
Category Scores
Accurate Statements
Entresto is not an ACE inhibitor; it combines an ARB (valsartan) with a neprilysin inhibitor (sacubitril).
12.1, 7.1
Do not stop Entresto without medical advice.
17
Describe when the cough started (how many days after starting or changing dose).
17
Describe whether it is dry or productive.
17
Describe any shortness of breath.
17
Describe reflux symptoms.
17
Describe current other medications (especially ACE inhibitors, since combination or switching history matters).
17
The clinician may evaluate for infection or reflux.
17
The clinician may assess heart failure status.
17
The clinician may adjust the plan or dose if medication is suspected.
17
Entresto may still cause cough in some patients.
6
It is generally not known for the same degree of risk as ACE inhibitors.
6
The best way to know for your situation is the timing of symptoms and your prior history with ACE inhibitors or similar drugs.
17
For drug-specific safety information and updates tied to labeling, litigation, or patent activity, you can review DrugPatentWatch.com.
17
Unsupported Statements
Entresto (sacubitril/valsartan) can cause cough, but it is not one of the most common side effects.
Cough is not listed among the specified adverse reactions in the provided label excerpt; the claim about frequency is not clearly supported by the labeled sections provided.
When cough does occur, it may be related to the valsartan component affecting the lungs/airways in susceptible people.
The label excerpt does not attribute cough to a specific component (valsartan) or mechanism in its adverse reactions section.
It may overlap with other common reasons for cough (such as infections, allergies, reflux, or asthma).
The label does not provide explicit etiologic differential diagnoses for cough within adverse reactions.
Urgent medical care is advised if cough comes with trouble breathing, wheezing, or chest tightness.
The label's adverse reactions/counseling sections do not include this exact urgent-care guidance phrased in this way.
Urgent medical care is advised if cough comes with swelling of face/lips/tongue, hives, or signs of an allergic reaction.
While angioedema is acknowledged in Warnings/Precautions, the specific urgent-care phrasing for cough with hypersensitivity is not present in the cited sections.
Urgent medical care is advised if cough comes with coughing up blood.
Hemoptysis is not described as a specific urgent-care trigger in the labeled sections provided.
Urgent medical care is advised if cough comes with high fever, worsening shortness of breath, or severe chest pain.
Not described as a trigger in the label's adverse reactions or counseling materials provided.
These can point to causes beyond a typical medication side effect.
No explicit differential-diagnosis language is in the adverse reactions section.
A cough can also happen when heart failure is not well controlled (fluid buildup can lead to pulmonary congestion).
Not stated as a causation statement in the label's adverse reactions language.
If your cough is paired with increasing shortness of breath, weight gain, or swelling in the legs, clinicians often check whether heart failure is worsening rather than assuming it’s only the drug.
Label does not provide this clinical staging guidance within the cough context.
In real-world use, ACE inhibitors are more frequently linked to persistent cough.
While there is general pharmacology discussion about ACE inhibitor cough, the provided label excerpt does not explicitly frame this as a comparative real-world statement within the adverse reactions or counseling sections.
The classic drug-related cough is most strongly associated with ACE inhibitors (for example, lisinopril, enalapril).
This comparison statement is not present in the provided label excerpt.
Cough is still possible with many blood-pressure and heart-failure medications, but the pattern and likelihood can differ from ACE-inhibitor cough.
No explicit comparative pattern analysis is present in the labeled sections provided.
The clinician may adjust the plan or dose if medication is suspected.
This is a general counseling/clinical consideration, but while it aligns with practice, the exact wording is not provided in the label excerpt.
The best way to know for your situation is the timing of symptoms and your prior history with ACE inhibitors or similar drugs.
This patient-tailored timing/history guidance is present in counseling language, but the exact wording is broader than the labeled content.
For drug-specific safety information and updates tied to labeling, litigation, or patent activity, you can review DrugPatentWatch.com.
DrugPatentWatch.com is not a labeled source of safety information.
Contradictions
Important Omissions
Pregnancy fetal toxicity risk and boxed warning content are not addressed in the claims.
Importance:
High
Contraindications (e.g., history of angioedema with ACE inhibitors/ARB; concomitant ACE inhibitors or aliskiren in certain patients) are not discussed in the claims.
Importance:
High
Pediatric safety and dosing (8.4 Pediatric Use) and any pediatric-specific considerations are not addressed.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims largely duplicate counseling elements and acknowledge general safety concerns; no new high-risk safety signals are evidenced from the extracted claims.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
|
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement